PT  - JOURNAL ARTICLE
AU  - Pazdernik, Michal
AU  - Gramegna, Mario
AU  - Bohm, Allan
AU  - Trepa, Maria
AU  - Vandenbriele, Christophe
AU  - De Rosa, Salvatore
AU  - Uzokov, Jamol
AU  - Aleksic, Milica
AU  - Jarakovic, Milana
AU  - El Tahlawi, Mohammad
AU  - Mostafa, Morsy
AU  - Stratinaki, Maria
AU  - Araiza-Garaygordobil, Diego
AU  - Gubareva, Ekaterina
AU  - Duplyakova, Polina
AU  - Chacon-Diaz, Manuel
AU  - Refaat, Hesham
AU  - Guerra, Federico
AU  - Cappelletti, Alberto Maria
AU  - Berka, Vojtech
AU  - Westermann, Dirk
AU  - Schrage, Benedikt
TI  - Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry
DP  - 2021 Sep 20
TA  - Biomedical papers
PG  - 291--297
VI  - 165
IP  - 3
AID - 10.5507/bp.2021.046
IS  - 12138118
AB  - Background. Concurrent evidence about cardiogenic shock (CS) characteristics, treatment and outcome does not represent a global spectrum of patients and is therefore limited. The aim of this study was to investigate these regional differences. Methods. To investigate regional differences in presentation characteristics, treatments and outcomes of patients treated with all types of cardiogenic shock (CS) in a single calendar year on a multi-national level. Consecutive patients from 19 tertiary care hospitals in 13 countries with CS who were treated between January 1, 2018 and December 31, 2018 were enrolled in this study. Results. In total, 699 cardiogenic shock patients were included in this study. Of these patients, 440 patients (63%) were treated in European hospitals and 259 (37%) were treated in Non-European hospitals. Female patients (P<0.01) and patients with a previous myocardial infarction (P=0.02) were more likely to present at Non-European hospitals; whereas older patients (P=0.01) and patients with cardiogenic shock due to acute heart failure (P<0.01) were more likely to present at European hospitals. Vasopressor use was more likely in Non-European hospitals (P=0.04), whereas use of mechanical circulatory support (MCS) was more likely in European hospitals (P<0.01). Despite adjustment for relevant confounders, 30-day in-hospital mortality risk was comparably high in CS patients treated in European vs. Non-European hospitals (hazard ratio 1.08, 95% CI 0.84-1.39, P=0.56). Conclusion. Despite marked heterogeneity in characteristics and treatment of CS patients, including fewer use of MCS but more frequent use of vasopressors in Non-European hospitals, 30-day in-hospital mortality did not differ between regions.